Drugs
In this section you will find Drugs market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2012
€999.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 89 companies plus partners who are today developing 88 Wnt pathway targeting drugs in 273 developmental projects in cancer across 97 different targets. In addition, there is 1 suspended drug and another 45 drugs where development has been ceased. Learn More -
Pancreatic Cancer Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 237 companies plus partners who are today developing 268 drugs targeting pancreatic cancer in development. across 198 different targets. In addition, there are 3 suspended drugs and another 95 drugs where development has been ceased. Learn More -
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2012
€499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 40 companies plus partners who are today developing 31 Hedgehog pathway targeting drugs in 123 developmental projects in cancer across 40 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More -
Renal Cancer Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 159 companies plus partners who are today developing 192 drugs targeting renal cancer in development. across 169 different targets. In addition, there are 4 suspended drugs and another 59 drugs where development has been ceased. Learn More -
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 207 companies plus partners who are today developing 264 Alpha6Beta4 integrin pathway targeting drugs in 848 developmental projects in cancer across 107 different targets. In addition, there is 1 suspended drug and another 125 drugs where development has been ceased. Learn More -
Melanoma Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 238 companies plus partners who are today developing 269 drugs targeting melanoma in development. across 182 different targets. In addition, there are 3 suspended drugs and another 113 drugs where development has been ceased. Learn More -
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2012
€499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 50 companies plus partners who are today developing 42 IL-7 pathway targeting drugs in 155 developmental projects in cancer across 45 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More -
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 237 companies plus partners who are today developing 288 TGF-beta receptor pathway targeting drugs in 815 developmental projects in cancer across 165 different targets. In addition, there are 2 suspended drugs and another 172 drugs where development has been ceased. Learn More -
FSH Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 157 companies plus partners who are today developing 178 FSH pathway targeting drugs in 610 developmental projects in cancer across 108 different targets. In addition, there are 2 suspended drugs and another 101 drugs where development has been ceased. Learn More -
Apoptosis in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 245 companies plus partners who are today developing 229 apoptotic drugs in 1003 developmental projects in cancer across 186 different targets. In addition, there are 8 suspended drugs and another 147 drugs where development has been ceased. Learn More -
RNA Interference Therapy in Oncology Drug Pipeline Update 2012
€999.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 43 companies plus partners who are today developing 58 RNA interference drugs in 75 developmental projects in cancer across 44 different targets. In addition, another 23 drugs where development has been ceased. Learn More -
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 105 companies plus partners who are today developing 110 IL-5 pathway targeting drugs in 354 developmental projects in cancer across 100 different targets. In addition, there is 1 suspended drug and another 47 drugs where development has been ceased. Learn More -
Biologicals in Oncology Drug Pipeline Update 2012
€2,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 669 companies plus partners who are today developing 1071 biological drugs in 2294 developmental projects in cancer across 408 different targets. In addition, there are 17 suspended drugs and another 676 drugs where development has been ceased. Learn More -
RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 164 companies plus partners who are today developing 192 RANKL pathway targeting drugs in 643 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 104 drugs where development has been ceased. Learn More -
Leukemia Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 249 companies plus partners who are today developing 321 leukemia drugs in 474 developmental projects in cancer across 208 different targets. In addition, there are 5 suspended drugs and another 104 drugs where development has been ceased. Learn More